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Abstract
Background: Drug-induced and drug-related deaths have been increasing for the past decade throughout
the US. In NYC, drug overdose accounts for nearly 900 deaths per year, a figure that exceeds the number
of deaths each year from homicide. Naloxone, a highly effective opiate antagonist, has for decades been
used by doctors and paramedics during emergency resuscitation after an opiate overdose. Following the
lead of programs in Europe and the US who have successfully distributed take-home naloxone, the
Overdose Prevention and Reversal Program at the Lower East Side Harm Reduction Center (LESHRC)
has started providing a similar resource for opiate users in NYC. Participants in the program receive a
prescription for two doses of naloxone, with refills as needed, and comprehensive training to reduce
overdose risk, administer naloxone, perform rescue breathing, and call 911. As of September 2005, 204
participants have received naloxone and been trained, and 40 have revived an overdosing friend or family
member. While naloxone accessibility stands as a proven life-saving measure, some opiates users at
LESHRC have expressed only minimal interest in naloxone use, due to past experiences and common
misconceptions.
Methods: In order to improve the naloxone distribution program two focus groups were conducted in
December 2004 with 13 opiate users at LESHRC to examine knowledge about overdose and overdose
prevention. The focus groups assessed participants' (i) experiences with overdose response, specifically
naloxone (ii) understanding and perceptions of naloxone, (iii) comfort level with naloxone administration
and (iv) feedback about increasing the visibility and desirability of the naloxone distribution program.
Results: Analyses suggest that there is both support for and resistance to take-home naloxone, marked
by enthusiasm for its potential role in reviving an overdosing individual, numerous misconceptions and
negative views of its impact and use.
Conclusion: Focus group results will be used to increase participation in the program and reshape
perceptions about naloxone among opiate users, also targeting those already prescribed naloxone to
increase their comfort using it. Since NYC is advancing toward a citywide naloxone distribution program,
the LESHRC program will play an important role in establishing protocol for effective and wide-reaching
naloxone availability.
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Background
Drug-induced mortality and morbidity have been increas-
ing throughout the United States over the past decade.
According to the Drug Abuse Warning Network, overdose-
related deaths in 30 US metropolitan areas rose from
5,000 in 1996 to 6,400 in 2002 [1]. As a result, for many
opiate users, experiencing overdose is a regular part of life.
Studies in Australia and the UK indicate that half to two-
thirds of sampled drug users had themselves previously
survived overdose, and a considerably greater number had
witnessed overdose by another drug user [2,3]. Overall,
regularly injecting heroin users face annual mortality rates
of two percent, a rate that is half attributable to overdose,
and six to 20 times the mortality rate expected in non-
drug-using peers [4-10].
In New York City, an estimated 900 opiate users die from
overdose each year, a figure that exceeds the number of
deaths from homicide [11]. Also in NYC, drug consump-
tion currently ranks among the five leading causes of mor-
tality in 15–54 year-olds, and comprises up to nine
percent of hospitalization in some neighborhoods [12-
14].
Opiates produce their effect by binding with neural recep-
tor sites at the expense of proper breathing function. In
the event of increased opiate consumption, breathing is
diminished and loss of consciousness occurs. Due to
unpredictable variables in drug strength or supply, or
reduced tolerance level after periods of cessation of use,
opiate overdose may be unavoidable, even if individuals
take preventative measures (i.e. knowing tolerance and
drug source, injecting slowly, not using alone). By no
means, however, must death be a necessary outcome.
Overdose is rarely instantaneous and usually happens in
the presence of others [10,15-18]. Bystanders may not
seek professional medical assistance due to fear of police
arrest, but can provide basic, effective care: mouth-to-
mouth resuscitation and naloxone hydrochloride, an opi-
ate antagonist also known as narcan. Administered most
commonly through injection, naloxone displaces opiates
at the receptor site, thereby restoring breathing and con-
sciousness within minutes [19]. Physicians and emer-
gency medical personnel in the US and throughout the
world have for decades been using naloxone to treat over-
dose patients. Few observed complications have been
reported, and existing reports of complications may be
unfounded [20]. While the administration of increased
doses of naloxone may incite withdrawal symptoms in
some patients who are opiate dependent, the drug is oth-
erwise harmless, exhibiting no potential for abuse and no
psychopharmacological effects [21].
Naloxone has been sold over the counter in Italian phar-
macies for more than ten years, and distributed to peer
networks of opiate users by European and U.S. harm
reduction programs since 1995. The Chicago Recovery
Alliance (CRA), a national leader in the field, has operated
one of the largest naloxone distribution programs to date.
In 2002, CRA equipped over 1,600 people with naloxone,
resulting in 115 lives saved and a 20 percent reduction in
fatal overdose, the first time in years this figure was in
decline [22]. San Francisco, Baltimore, and parts of New
Mexico have also distributed naloxone to opiate users
through needle exchange and methadone maintenance
programs.
Similar work has recently begun at the Lower East Side
Harm Reduction Center (LESHRC) in NYC through an
on-site intervention called the Overdose Prevention and
Reversal Program. LESHRC serves over 9,000 opiate users
annually with clean needles and other support services,
and is the first in NYC to distribute naloxone to its pro-
gram participants. Recruiting opiate users as individuals,
pairs, or groups, trained LESHRC staff and volunteers pro-
vide instruction in overdose risk and prevention,
naloxone administration, calling 911, follow-up care, and
interfacing with police. The program aims to 1) decrease
the alarmingly high incidence of overdose-related death;
2) increase overdose awareness and preparedness; 3)
encourage individuals to reflect upon personal overdose
risk; and 4) facilitate dialogue between drug using part-
ners regarding proper overdose response. As of September
2005, naloxone has been prescribed to over 204 LESHRC
program participants, and 40 cases of successful overdose
reversal with the use of peer-administered naloxone have
been reported.
Current literature on opiate overdose has recognized the
importance of naloxone distribution as an effective harm
reduction tool. In the fall of 2004, a group of researchers
and service providers from the Center for Urban Epidemi-
ologic Studies (CUES) at the New York Academy of Med-
icine and LESHRC looked to build upon this
recommendation. They conducted focus groups with opi-
ate users from LESHRC to assess knowledge of overdose,
overdose prevention, and overdose response, as well as
attitudes about naloxone, naloxone experiences and sup-
port for its availability as a take-home medication.
Because only few studies have asked opiate users to
address topics specific to naloxone, the goal is to contrib-
ute to literature on opiate overdose by offering first-hand
accounts of naloxone experience. Focus group results will
be used to increase participation in the program, reshape
perceptions about naloxone among opiate users, and
encourage naloxone comfort among those who carry it as
a result of the program.Harm Reduction Journal 2006, 3:19 http://www.harmreductionjournal.com/content/3/1/19
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Methods
In December of 2004, two focus groups were convened at
LESHRC. Study participants were recruited by means of
in-house flyers, word of mouth, and referral by LESHRC
staff members. Eligibility for the first focus group was
determined by opiate use; for the second, completion of
the Overdose Prevention and Reversal Program and
receipt of naloxone. All study participants were over the
age of 18. The first focus group had eight participants,
three of whom were African-American females; the
remaining five included one African-American male, one
Hispanic male, and three White males. In the second
focus group, there was a total of five participants, one Afri-
can-American male and four White males. Two trained
CUES and LESHRC staff members facilitated the first
group using an open-ended question guide, which
accessed participants' 1) experiences with overdose
response, specifically naloxone; 2) understanding and
perceptions of naloxone; 3) potential comfort level with
naloxone administration; and 4) feedback about increas-
ing the visibility and desirability of a naloxone distribu-
tion program. The second focus group was conducted by
the above LESHRC staff member and a LESHRC program
director using the same question guide, along with addi-
tional questions that addressed prior experience using
naloxone on an overdosing friend, to examine naloxone
comfort.
The focus groups were audio taped and later transcribed.
To ensure anonymity, names were not recorded and tapes
were destroyed immediately after transcription. Study par-
ticipants received $15 compensation as well as transporta-
tion reimbursement. Group participation was voluntary,
and study participants were welcome to decline from fur-
ther participation at any point in time. Study goals and
study protocol were clearly outlined at the start of each
group, followed by the collection of verbal consent from
each study participant. The themes presented in this paper
emerged from the focus groups transcripts and were
derived by two of the authors using a coding system which
included open and axial coding. During open coding,
each coder independently 1) studied the textual material;
2) pinpointed quotes recurring throughout the text; 3)
examined them vis-à-vis related or contradictory quotes
also in the text; and 4) organized them into major themes.
As part of axial coding, the coders compared notes, nego-
tiating which themes provided the richest, most saturated
understanding of the study participants' knowledge about
overdose and naloxone.
Results
Participants in both focus groups expressed mixed feelings
about naloxone in the context of overdose, including
some hesitation to its distribution for take-home use. In
our review of transcripts, we identified four major themes
to capture the overall views of participants: 1) support for
naloxone as a lifesaving measure; 2) challenges of admin-
istering naloxone during an overdose; 3) fear of dopesick-
ness; and 4) fear of police arrest at the scene of an
overdose after naloxone administration.
Naloxone as lifesaving measure
Study participants unanimously recognized the potential
role of naloxone in successfully reviving someone from an
unconscious, overdose-induced state. Not surprisingly,
most enthusiastic were participants who had already com-
pleted the Overdose Prevention and Reversal Program
and received naloxone. As one participant described:
"This particular program with the naloxone...gives me a feeling
of, of security. And not so much for myself, because...to tell you,
to be honest, I've been using...heroin now for close to 30 some-
thing years and I have never once overdosed... However, I have
a lot of friends, and a lot of my close friends...are also users,
so...it gives me a feeling of security for them. To be able to help
them, just in case one of them goes off the deep end...and over-
doses... At least...I feel like a guardian angel, I guess."
These words demonstrated both an understanding of the
breadth of fatal overdose – that is, any drug user is at risk
– as well as a personal commitment to saving the life of a
friend, however possible. Another participant expressed
similar sentiment. She shared her experiences intervening
in overdose scenarios over the years. Compared to the
unproven and potentially dangerous resuscitation meth-
ods such as causing pain and applying ice, she described
naloxone as "such a godsend" because she now "can give
'em that before the ambulance" arrives. The administra-
tion of naloxone to an overdose victim while awaiting
more comprehensive medical care was imperative to this
participant, considering both the urgency of a non-breath-
ing individual, and the fact that ambulances are some-
times not as quickly dispatched to overdose calls. She
explained, "A lot of times, fifteen, 20 minutes, if the
ambulance doesn't show up, [the overdosed person]
could be dead." Naloxone provided her not a substitute
for calling 911 but a sense of security while awaiting an
ambulance.
Non-naloxone-holding participants also voiced support
for the potential role of naloxone to revive someone.
However, they pointed to its merit as a necessary step only
when other attempts proved unsuccessful and the conse-
quence of death would be too much to bear. One partici-
pant stated:
"Narcan is good, when you're like, it's the last resort. I mean,
you can't get them up, you put 'em in the shower, you rubbed
ice on their scrotum, you've given them mouth-to-mouth resus-
citation, you've pumped their chest, you've tried."Harm Reduction Journal 2006, 3:19 http://www.harmreductionjournal.com/content/3/1/19
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Another participant confirmed that he would "rather have
narcan than die," despite the unpleasant symptoms of
withdrawal that sometimes accompany its use. These par-
ticipants, in particular, were clear about their support for
naloxone, and furthermore, qualified the exact circum-
stances in which they would use it.
Challenges of administering naloxone
Accounts of naloxone perception and experience were not
entirely favorable. Participants reported challenges and
fears when they reflected upon personal experiences of
naloxone being administered to them or their administer-
ing it to others.
An overdose situation can be scary, chaotic, and emotion-
ally traumatic. Bystanders untrained in proper overdose
response may become paralyzed with fear or attempt to
revive the person using less effective measures. In antici-
pation of police involvement, others may be over-
whelmed with securing their own safety, frantically
discarding evidence of drugs or drug paraphernalia, or
planning their escape in fear of being charged with man-
slaughter. The sight of an overdosing friend or family
member can also be distressful. The stress of an overdose
situation was clearly described by focus group participants
with extensive overdose experience. As one participant put
it:
"Every time I've been in the situation where someone ODs, it's
a panic, and ...I've always kept my cool, but everybody else
around and yellin' and screamin'...and losin' their head,
and...runnin' round like a chicken with their head cut
off...they're scared for this person's life."
When naloxone is available, the situation is not necessar-
ily improved. Among focus group participants, only one
reported administering naloxone to an overdosing friend,
who was then revived. He described the situation as hec-
tic, himself struggling to remain calm enough to perform
the injection with precision and ease.
"And you don't want to make a mistake, you know? You don't
have to look for a vein...but...it's a very shaky...scary situation...
I'm not looking for directions... You're nervous as hell!"
Administering naloxone can be even more complicated
when the person trained to administer it is himself intox-
icated. The same participant explained, "especially if
you're messed up... and all five people are... high as a kite,
you know... it's gonna be total panic." For this participant,
the difficulty of administering naloxone, compounded by
the fear that his intoxication level may pose additional
barriers, were so profound that he was reluctant to receive
a naloxone refill. Although he recognized the vital role of
naloxone in the outcome of the event, he was unsure he
could use it again.
Fear of dopesickness
Dopesickness – or opiate withdrawal characterized by
shaking, headache, nausea, and vomiting – was a promi-
nent theme among study participants. Naloxone, particu-
larly in larger doses, can incite withdrawal symptoms in
opiate users. Focus group participants who had been
given naloxone by emergency medical personnel
described the effect as "the worst feeling in the world." In
recounting his overdose experience, one participant
reported being revived with only mild discomfort after a
single naloxone injection, but when EMS administered a
second dose, the physical result was unbearable:
"I was COLD... I was SWEATIN'...I was freezin'...like some-
body just took the plug out and 'Oh, no. That pleasure is gone'
...having fever and chills at the same time... Everything hurts.
Your whole body hurts. Uh, 'cause you're convulsing."
Other participants who had been given naloxone during
an overdose confirmed reports of excruciating pain, citing
that it was not an experience they wished to repeat.
Enduring dopesickness post-naloxone use presented fur-
ther concerns for some study participants, who affirmed
that if naloxone were ever used on them, they would have
no choice but to use more opiates to ease the discomfort.
As one participant noted, after naloxone, "Now you're ill
again, so you gotta get MORE money to get high, 'cause
now you're sick!" Another added, "You gonna have to go
cop again... So even if you don't wanna, you're gonna go
get it anyway." The perceived need to counteract with-
drawal by using again highlights a common misconcep-
tion. In truth, because naloxone only lasts 30 to 90
minutes after administration, any additional opiate con-
sumption increases the chances of a subsequent overdose
once the naloxone wears off. The above study partici-
pants, who had some naloxone experience but no formal
training, were therefore familiar with its function and
physiological effect but lacked important information
that would lead to effective follow-up care.
Even some of the participants with formal naloxone train-
ing were misguided on how to proceed once administer-
ing naloxone to an overdosing friend or family member.
They understood the risks of subsequent overdose with
increased opiate use, but were not convinced that waiting
until the naloxone wears off qualified as best practice.
Speaking hypothetically about reviving someone with
naloxone, one participant explained:
"If I had the money, I would think I would like to get 'em
straight, but I'd be afraid he'd go right back into overdose, so IHarm Reduction Journal 2006, 3:19 http://www.harmreductionjournal.com/content/3/1/19
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wouldn't do it. But if anything, I would give 'em a little meth-
adone."
Although the study participant demonstrated an aware-
ness that both dopesickness and subsequent overdose are
associated risks of naloxone, his prioritizing immediate
withdrawal relief could be potentially dangerous. Dope-
sickeness, unlike overdose, is non-fatal and in cases where
naloxone has been administered, will subside without fur-
ther medicating. A subsequent overdose could also be
effectively reversed; however, it would require additional
doses of naloxone that may be unavailable to the over-
dose responder.
Fear of police
The final theme presented by the focus groups was fear of
police involvement at the scene of an overdose after
naloxone administration. These fears were less about indi-
viduals having drugs on them when police arrived, and
more about liability if they used their naloxone on a third
party, which at the time of writing was legally suspect.
Such fears were compounded by past experience, in which
police officers rarely elicited information before perform-
ing arrests, and furthermore, treated all drug users at the
scene of an overdose as responsible parties. In reflecting
upon situations where she would use naloxone, one par-
ticipant stated:
"There is the police factor... So you might be more scared about
the damn cops than saving someone's life. So that's the choice
you gotta make. You might be facin' some serious time."
Participants who shared this view requested additional
training in how to effectively communicate with police
officers who arrive at the scene of an overdose, particularly
if they have used their naloxone on someone without a
naloxone prescription.
The desire to save another person whatever the conse-
quence, however, overpowered these fears in the case of
other participants. One participant explained, "If I see a
person's life on the line, my first thought would be, the
first thing, to just bring them revival." Using naloxone
beyond its recommended purpose, from his view, was a
risk worth taking.
Discussion
Focus group results show that naloxone is undeniably
advantageous for individuals to effectively revive an over-
dosing friend or family member, instead of resorting to
potentially harmful and less effective methods of resusci-
tation. Participants' narratives also point to other consid-
erations – the challenges of administering naloxone, fear
of dopesickness, and fear of police. All of these areas
reveal some benefits and challenges to naloxone training
as a critical arena for overdose prevention, and offer
important insights for improving overdose prevention
and reversal efforts.
Support for naloxone as a lifesaving measure is shared by
opiate users around the world. One study shows that 70
percent of sampled opiate users voiced support for
naloxone as a take-home medication, and 49 percent
reported a willingness to keep supplies on hand [23].
These results have caused some concern that witnesses to
an overdose would therefore use naloxone as a substitute
for calling 911 [23-25]. As indicated by focus group par-
ticipants, however, naloxone is considered an acceptable
last resort while awaiting the arrival of trained emergency
medical personnel. Although fear of police arrest was
reported as a complicating factor, no participant expressed
adamant refusal to involving the medical system, suggest-
ing that widespread availability of naloxone may not
negate messages to overdose responders that follow-up
medical care be standard practice for any overdose.
The commitment to being a most effective overdose
responder, however, has its drawbacks. As indicated by
some study participants, the primary motivation for
enrolling in a naloxone distribution program was to help
an overdosing friend or family member, which may mean
that personal perceptions of overdose risk are being
largely ignored or overlooked. Another study found that
approximately half of the study sample reported an over-
dose over the course of six months, yet almost three-quar-
ter of the respondents had rarely or never worried about
the possibility of overdosing during the same time period
[24]. Participants in our study, and opiate users in general,
may need more encouragement to reflect upon personal
overdose risk, which ultimately may be the most effective
measure to save lives.
The challenges of take-home naloxone (i.e. the impact of
panic and intoxication on successful naloxone adminis-
tration) reported by some of the study participants and in
other studies [26,27] offer another important insight.
Considering that individuals could gain comfort and con-
fidence using naloxone through practice or follow-up
training, naloxone distribution programs may consider
arranging multiple visits with enrolled participants to
review protocol, practice role plays of naloxone adminis-
tration, provide support, and address fears.
Also noteworthy was the aversion some study participants
had to past or anticipated naloxone experiences. The
study participant who had used naloxone on a friend
described the events as challenging, stressful, and emo-
tionally upsetting, and the others who had received
naloxone, or even only heard of it, were discouraged by
the potential for dopesickness post-administration. ThisHarm Reduction Journal 2006, 3:19 http://www.harmreductionjournal.com/content/3/1/19
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refutes concerns that take-home naloxone could encour-
age riskier drug-taking activity in opiate users who would
be therefore comfortable using beyond their tolerance,
knowing a friend could quickly revive them in the event
they overdosed [28,29].
The threat of dopesickness, however, could effect partici-
pant interest in naloxone distribution programs. In partic-
ular, fears of dopesickness may have been one of the
factors that deterred participants from immediately
enrolling in the Overdose Prevention and Reversal Pro-
gram where naloxone distribution was publicized as the
primary aim. Although these study participants reported
that they would rather receive naloxone than die, they
may have also been trying to avoid situations with
naloxone entirely. This identifies a need to promote pre-
vention and intervention strategies focused on overdose
where naloxone is not the main feature, in order to cap-
ture the attention of opiate users who would otherwise
remain disconnected.
Opiate users' strong feelings about withdrawal symptoms
post-naloxone also indicates that they may ignore warn-
ings against continued opiate consumption after an over-
dose reversal. Although premature re-consumption of
heroin or other opiates rarely leads to a subsequent over-
dose once naloxone wears off [30], the issue should not be
ignored. There may be a need for increased education and
resources for individuals to support a friend regaining sta-
bility after an overdose event. While encouraging partici-
pants to seek medical help is one option, another may be
distributing naloxone alongside controlled amounts of
buphrenorphine or methadone, so they may experience
some degree of immediate withdrawal relief.
Fear of police in our study revealed that participant con-
cerns were less about potentially facing charges for posses-
sion of drugs, possession of drug paraphernalia, or
manslaughter, and more about the consequences if they
used their naloxone on a non-prescription holding indi-
vidual. While literature confirms that drug possession and
manslaughter are not major deterrents to calling 911 [3],
only minimal attention has been given to fears about
administering naloxone to a third party. New Mexico has
most effectively addressed this issue by providing legal
protection to anyone, physician or bystander, administer-
ing naloxone to opiate victims with or without naloxone
prescription. To increase the comfort and feasibility of
naloxone use throughout the US, state legislative bodies
should take similar action steps (see appendix 1).
Conclusion
In summary, these focus groups highlighted the strengths
and weaknesses of naloxone distribution programs, as
well as indicated areas for further exploration. The lessons
learned are useful for several reasons. First, they merit the
attention of researchers and service providers committed
to improving overdose intervention strategies nationwide.
Second, they provide a framework for new naloxone pro-
gramming taking place in NYC. Soon after LESHRC began
its naloxone program, the NYC Injection Drug User
Health Alliance obtained funding for similar overdose
prevention and reversal efforts, including naloxone distri-
bution, at consenting needle exchange programs. Our
study results, considering their geographic relevance, serve
to inform NYC-based needle exchange programs as they
continue to develop effective services for opiate users to
reduce overdose risk, as well as to assist friends and fam-
ily. The findings also benefit any drug- or non-drug-using
individual who has connections with opiate users and
may be able to intervene in a time of need. Future research
will need to assess the continued viability of take-home
naloxone, once naloxone programs have refined training
strategies to address fear of dopesickness and police, and
the challenges often associated with an overdose event.
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Appendix 1
On August 2, 2005, Governor George Pataki signed a bill
regarding opiod overdose prevention that authorizes 1)
the state health commissioner to establish standards for
overdose prevention programs and 2) the use of naloxone
by non-medical staff in the case of an overdose. The law
takes effect in April 2006. Such legislation will hopefully
increase awareness of overdose prevalence and increased
naloxone use in overdose prevention among opiate users.
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